The YAP–TEAD complex is a viable drug target, and CPD3.1 is a lead compound for the development of more potent TEAD inhibitors for treating cancer and other hyperproliferative pathologies. Here, we ...

The decision was based on the results of the phase III ARANOTE trial, in which researchers randomly assigned 669 patients in a 2:1 fashion to receive the androgen receptor inhibitor plus androgen ...

‡ Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China § CAS Key Laboratory of ...

Background: Despite the unprecedented advancement of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in the treatment paradigm for hormone-dependent breast cancer, reports of cardiovascular ...

This study provides valuable findings that MK2 inhibitor CMPD1 can inhibit the growth, migration and invasion of breast cancer cells both in vitro and in vivo. The evidence supporting the claims of ...

BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the most common treatment for CML. These drugs seem to work best when ...

SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in ...

Accropeutics’ drug has hit the goals of a phase 2 psoriasis trial in China, prompting the biotech to pledge to “accelerate” the TYK2/JAK1 inhibitor’s clinical development. The study saw ...